Mallinckrodt expands rights to imaging agent:
This article was originally published in Clinica
Executive Summary
Mallinckrodt's marketing rights for Molecular Biosystem's imaging agent, FS609, will now encompass Europe, Africa, India and Russia as well as the US. In October, the two companies submitted a PMA to the US FDA for the agent, and they intend to seek market clearance in Europe in early 1997. Mallinckrodt will pay $12.9 million for the rights as well as 40% of product sales to cover royalties and manufacturing. An initial payment of $7.1 million is payable within 30 days, with the remainder becoming due as agreed milestones are met.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.